Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
_↗ yoltx.com
News Image

YolTech Therapeutics, a clinical-stage biotech company specializing in in vivo genome editing therapies, has successfully closed an approximately $45 million Series B financing round. The funding, led by the AstraZeneca-CICC healthcare investment fund, will be used to advance YolTech's clinical programs and support its global strategic operations. Founded in 2021, the company focuses on developing one-time, next-generation in vivo gene-editing therapies. Its fully integrated platform includes proprietary CRISPR nucleases (YolCas), base editors (YolBE), and an advanced lipid nanoparticle delivery system (Yol-LNPs), which enables precise, efficient, and tissue-specific gene editing across various therapeutic areas., a clinical-stage biotech company specializing in in vivo genome editing therapies, has successfully closed an approximately $45 million Series B financing round. The funding, led by the AstraZeneca-CICC healthcare investment fund, will be used to advance YolTech's clinical programs and support its global strategic operations. Founded in 2021, the company focuses on developing one-time, next-generation in vivo gene-editing therapies. Its fully integrated platform includes proprietary CRISPR nucleases (YolCas), base editors (YolBE), and an advanced lipid nanoparticle delivery system (Yol-LNPs), which enables precise, efficient, and tissue-specific gene editing across various therapeutic areas.

YolTech has a robust clinical pipeline, with four programs currently in the clinical stage. In 2024, its lead program, YOLT-201, a CRISPR-based therapy for transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in China to enter a Phase I/IIa clinical trial. The company has since advanced programs addressing familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD). Additionally, the company's base-editing therapy, YOLT-101 for familial hypercholesterolemia (HeFH), holds the distinction of being the first in vivo base-editing program to receive IND clearance in both China and the United States. With one of the most extensive in vivo gene-editing clinical pipelines globally, YolTech operates its own cGMP-compliant manufacturing facility, which supports clinical supply through Phase III and early commercial scale-up, ensuring consistency and scalability for its programs.

Log In
Sign Up